Pharma News

GSK plc announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anaemia. Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor.

Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain. The transaction includes an upfront cash payment of 850 million USD and undisclosed additional contingent payments based on sales performance over the next three years.

An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma has reported initial results in the Journal of Clinical Oncology. While none of the three therapeutics tested so far improved overall survival of patients, this adaptive platform trial, the first of its kind in neuro-oncology, has the potential to rapidly and efficiently identify therapies that benefit patients.

New research provides insight about the bedrock scientific principle that mitochondrial DNA — the distinct genetic code embedded in the organelle that serves as the powerplant of every cell in the body — is exclusively passed down by the mother.

ProMyelocytic Leukemia (PML) protein controls various biological functions, such as apoptosis, senescence or stem cell self-renewal. PML may elicit these functions by scaffolding the spherical shells of PML Nuclear Bodies (NBs), which subsequently act as hubs of post-translational modifications, in particular sumoylation, for the broad range of proteins trafficking through their inner cores. PML NBs are disrupted in Acute Promyelocytic Leukemia (APL) driven by the PML-RARA oncogenic fusion protein.

Strides Pharma Science Limited announced that its step‐ down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received tentative approval for its New Drug Application (NDA) 505b2 of Dolutegravir/ Lamivudine/ Tenofovir Disproxil Fumurate 50mg/ 300mg/ 300mg tablets from the United States Food & Drug Administration (USFDA). The Product will be manufactured at the company’s facility in Bengaluru.

Breast cancer research takes a significant stride forward as Professor Semin Lee and his research team from the Department of Biomedical Engineering at UNIST, in collaboration with Professor Ji-Yeon Kim and Professor Young-Hyuck Im from the Division of Hematology-Oncology at Samsung Medical Center in Seoul, delves into the exploration of triple negative apocrine carcinoma. This rare breast cancer subtype has garnered attention due to its unique genetic characteristics and improved prognosis when compared to other forms of triple-negative breast cancer (TNBC).

A study  led by Columbia obstetricians has shown that a new intrauterine device can rapidly control postpartum hemorrhage, a major cause of severe maternal morbidity and death, in real-world situations.

An LSU Health New Orleans research study led by Siqiong June Liu, PhD, Professor of Cell Biology and Anatomy, has found that cerebellar inhibitory interneurons are essential for fear memory, a type of emotional memory formation. Inhibitory interneurons within the cerebellar circuitry act as gatekeepers and control the output of the cerebellar cortex. The formation of fear memory requires the activity of these interneurons.